Please join us for a Nektar-hosted investor-investigator breakfast at the 2010 ASCO meeting in Chicago. The Monday breakfast session will include a presentation on NKTR-102/NKTR-105 and a review of the Phase 2 data in ovarian cancer for NKTR-102. Click here to RSVP today and download to your calendar »
Nektar's Chief Medical Officer, Dr. Lorianne Masuoka, will also moderate a Q&A panel with ovarian cancer experts, including:
Dr. Ignace Vergote - The lead investigator for Nektar's Phase 2 study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer. Dr. Vergote is Professor and Chairman of the Dept. of Obstetrics and Gynaecologic Oncology at Catholic University of Leuven in Belgium.
Read Full Bio »
Dr. Robert L. Coleman - An independent key opinion leader in ovarian cancer. Dr. Coleman is Professor and Director of Clinical Research of the Department of Gynecologic Oncology at University of Texas M. D. Anderson Cancer Center, Houston, TX.
Read Full Bio »
Dr. Daniel Von Hoff - Recipient of the 2010 David A. Karnofsky Memorial Award at this year's ASCO meeting and lead investigator for Nektar's Phase 1 study of NKTR-102. Dr. Von Hoff is an internationally recognized physician-scientist who has contributed to the development of numerous anticancer agents, including paclitaxel, docetaxel, irinotecan and gemcitabine. He also is the Chief Scientific Officer of TGen Clinical Research Services at Scottsdale Healthcare and at US Oncology, and is a Clinical Professor of Medicine at the University of Arizona College of Medicine.
Read Full Bio »
Data from Nektar's Phase 2 clinical study in women with platinum-resistant ovarian cancer will be presented in an oral podium session on Sunday, June 6, 2010 at 11:15 a.m. Central Time in the E Arie Crown Theater at the McCormick Convention Center in Chicago.
The oral abstract presentation entitled "Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer" (Abstract #5013), will be featured in the Oral Abstract Session for the Gynecologic Cancer Track. The data will be presented by the lead investigator in our Phase 2 study, Prof. Dr. Ignace Vergote, Professor and Chairman of the Dept. of Obstetrics and Gynaecologic Oncology at Catholic University of Leuven in Belgium.
In addition, Nektar's ongoing Phase I clinical trial of NKTR-105 in advanced solid tumors will be featured in the new "Trials in Progress" poster session on Monday, June 7, 2010 starting at 8:00 a.m. The poster is titled, "Dose-escalation Phase 1 study of NKTR-105, a novel pegylated form of docetaxel" (Abstract #TPS160).
Biographies of Panel Participants
Prof. Dr. Ignace B. Vergote, European Union
Professor, Head of the Department of Obstetrics and Gynaecology and Gynaecologic Oncology, Catholic University of Leuven, Belgium.
Dr. Vergote, initially trained in Obstetrics and Gynaecology at the University of Antwerp, Belgium, before specialising in Gynaecologic Oncology in the Department of Gynaecologic Oncology at the Norwegian Radium Hospital, where he later became staff member and in 1991 deputy chairman.
Professor Vergote has been Chairman of the European Organization for Research and Treatment of Cancer (EORTC) Gynecologic Cancer Group from 1997 to 2003, and is currently the chairman of the Protocol committee of that group.
He served as President of the European Society of Gynaecological Oncology (ESGO) for the period 2003-2005. For the period 2006-2008 he was the President of the International Gynecologic Cancer Society (IGCS). He was the founding member of the Flemish Gynecologic Oncology Group and served as first chairman of that group from 1996-2001. Currently, he is the Chairman of the Flemish Society of Obstetrics and Gynaecology, Vice-President of the Society of Robotic European Gynaecological Surgery (SERGS) and Coordinator of the European Network of Gynaecological Oncological Trial groups (ENGOT).
In 2004 he received the Wertheim price in Austria and the COBRA price for surgical expertise in the Netherlands. In 2008, he became Honorary Member of the Finish Society of Gynaecology and Obstetrics. He is a member of various other professional societies such as the American Society of Clinical Oncology, the Society of Gynecologic Oncology and the Society of Pelvic Surgeons.
Professor Vergote's main areas of clinical and research interest focus on the medical and surgical treatment of gynaecological cancer. He has authored 450 original full papers in peer-reviewed journals, together with 50 book chapters, and edited several books on Gynaecological Oncology. He is also Senior Editor of the International Journal of Gynaecological Cancer, and past-Associate Editor of Gynecologic Oncology. He is also member of the Editorial Board of numerous other medical journals such as the Journal of Clinical Oncology.
Return to top »
Robert L. Coleman, M.D., FACOG, FACS
Professor, Department of Gynecologic Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX
Director of Clinical Research, Department of Gynecologic Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX
Dr. Coleman was recruited back to the M.D. Anderson faculty in 2004 to help expand and coordinate the Department of Gynecologic Oncology clinical therapeutics program. Finishing the institution's Gynecologic Oncology fellowship in 1993, he has distinguished himself as a key opinion leader in cancers of the female genital tract. He has authored and co-authored numerous peer-reviewed scientific publications, book chapters, monographs, invited articles and textbooks including, The Handbook of Gynecologic Oncology, Clinical Lymphatic Mapping in Gynecologic Cancers and Prognostic and Predictive Factors in Gynecological Cancers. He is a frequently invited lecturer for national and international conferences and meetings where he continues to foster international scientific collaboration.
Before returning to M.D. Anderson, Dr. Coleman served as Division Director of Gynecologic Oncology at Creighton University School of Medicine and Vice-Chairman of Obstetrics and Gynecology at The University of Texas Southwestern Medical Center in Dallas. There he held the inaugural Patricia Duniven-Fletcher Professorship of Gynecologic Oncology. Dr. Coleman's research interests include novel therapeutics for ovarian, uterine and cervical cancer, clinical trial development and statistical design, surgical innovations and graduate education. He is the institution's Gynecologic Oncology Group (GOG) Principal Investigator (PI) and is PI or Co-PI for several GOG prospective clinical trials including a national, multicenter, randomized trial evaluating chemotherapy and surgery for recurrent ovarian cancer, several trials of novel chemotherapeutics and biologics in cancers of the ovary, cervix and uterus and two trials evaluating lymphatic mapping for gynecologic malignancies. He currently is a co-Project leader for the MDACC Ovarian SPORE, The Ovarian Cancer Research Fund, and the Marcus Foundation, each of which is sponsoring novel therapeutics trials in gynecologic cancers.
Dr. Coleman currently serves on the Editorial Board of several peer-reviewed scientific publications. He is an active member of many national organizations including the Society of Gynecologic Oncologists, the American College of Surgeons and the American Society of Clinical Oncology. Dr. Coleman serves as the chairman of the Department of Gynecologic Oncology Research Administration Committee, is a member of the Blanton-Davis Ovarian Cancer Research Program Executive Committee and is a Member of the Board for the Gynecologic Cancer Foundation.
Return to top »
Daniel D. Von Hoff, M.D.
Professor of Medicine, Pathology, Molecular and Cellular Biology, Director of the Arizona Health Sciences Center's Cancer Therapeutics Program
Executive Vice President, Translational Genomics Research Institute (TGen)
Director, TGen's Translational Drug Development Division and Head, Pancreatic Cancer Research Program Chief Scientific Officer for US Oncology
Dr. Von Hoff's major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, CPT-11, and others. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies.
Dr. Von Hoff's laboratory interests and contributions have been in the area of in vitro drug sensitivity testing to individualize treatment for the patient. He and his laboratory are now concentrating on discovery of new targets in pancreatic cancer. Dr. Von Hoff has published more than 515 papers, 127 book chapters, and more than 850 abstracts. Dr. Von Hoff was appointed to President Bush's National Cancer Advisory Board in June 2004 - March 2010. Dr. Von Hoff is the past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEXTM Oncology, Inc. (recently acquired by Genzyme).
Dan Von Hoff has devoted his career to translational medicine, which is defined as movement of new therapies from the research institution into patient care. He currently serves as the Executive Vice President, Senior Investigator and Head of Translational Research at the Translational Genomics Research Institute's (TGen) Translational Drug Development Division and heads its Pancreatic Cancer Research Program. He is also Professor of Medicine, Molecular and Cellular Biology and Pathology at the University of Arizona and served as director of the Arizona Cancer Center. He also serves as Chief Scientific Officer for US Oncology and the Scottsdale Clinical Research Institute. In addition, he provides expertise as a founder or medical/scientific advisor to a broad range of companies working toward a cure for cancer. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.
After graduating cum laude from Carroll College, Dr. Von Hoff received his M.D. from Columbia University College of Physicians and Surgeons. He completed his internship and residency in internal medicine at the University of California, San Francisco, then completed a medical oncology fellowship at the National Cancer Institute. Dr. Von Hoff then moved to the University of Texas Health Science Center at San Antonio, where he rose to Professor in the Department of Medicine and the Department of Cellular and Structural Biology. In 1989, Dr. Von Hoff became the Founding Director of the Institute for Drug Development at the Cancer Therapy and Research Center in San Antonio. In 1999, he became Director of the Cancer Center and Professor of Medicine at the University of Arizona.
Dr. Von Hoff has served as editor of numerous scientific publications. He is founder and Editor Emeritus of Investigational New Drugs - The Journal of New Anticancer Agents as well as the current Editor-in-Chief of Molecular Cancer Therapeutics. Previously he was the associate editor of Cancer Research and Clinical Cancer Research. Dr. Von Hoff has also served on the editorial boards of the American Journal of Medicine, Anticancer Drugs, Oncology, Annals of Oncology, and nine other scientific journals. |
